<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kpccz</journal-id><journal-title-group><journal-title xml:lang="ru">Комплексные проблемы сердечно-сосудистых заболеваний</journal-title><trans-title-group xml:lang="en"><trans-title>Complex Issues of Cardiovascular Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-1278</issn><issn pub-type="epub">2587-9537</issn><publisher><publisher-name>Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17802/2306-1278-2025-14-1-169-179</article-id><article-id custom-type="elpub" pub-id-type="custom">kpccz-1570</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНЛАЙН. ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ. Кардиология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONLINE. ORIGINAL STUDIES. CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>ВЛИЯНИЕ СЕРДЕЧНО-СОСУДИСТОЙ ПАТОЛОГИИ НА РИСКИ РАЗВИТИЯ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ ПАЦИЕНТОВ</article-title><trans-title-group xml:lang="en"><trans-title>IMPLICATION OF CARDIOVASCULAR PATHOLOGY ON THE RISKS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8118-0522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Заикина</surname><given-names>Маргарита Павловна</given-names></name><name name-style="western" xml:lang="en"><surname>Zaikina</surname><given-names>Margarita P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры факультетской терапии № 1 федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>Postgraduate student of the Department of Faculty Therapy No. 1, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">zaikina.rita@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2252-7773</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткачёв</surname><given-names>Максим Игоревич</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachev</surname><given-names>Maksim I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук доцент кафедры сердечно-сосудистой хирургии института профессионального образования федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>PhD, Associate Professor of the Department of Cardiovascular Surgery at the Institute of Professional Education, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">maximtkachev1997@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7802-1843</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Когай</surname><given-names>Вероника Валерьяновна</given-names></name><name name-style="western" xml:lang="en"><surname>Kogaj</surname><given-names>Veronika V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры факультетской терапии № 1 федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>Postgraduate student of the Department of Faculty Therapy No. 1, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">veronika.kogay@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-1516-7278</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Табаченкова</surname><given-names>Елизавета Сергеевна</given-names></name><name name-style="western" xml:lang="en"><surname>Tabachenkova</surname><given-names>Elizaveta S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>студент 6-го курса федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>6th year student, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">tabachenkovaelizaveta@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0160-6015</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудрявцева</surname><given-names>Анна Александровна</given-names></name><name name-style="western" xml:lang="en"><surname>Kudryavceva</surname><given-names>Anna A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры факультетской терапии № 1 федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>Assistant of the Department of Faculty Therapy No. 1, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">kudryavtseva_a_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6241-2711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Напалков</surname><given-names>Дмитрий Александрович</given-names></name><name name-style="western" xml:lang="en"><surname>Napalkov</surname><given-names>Dmitrij A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук профессор кафедры факультетской терапии № 1 федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>PhD, Professor of the Department of Faculty Therapy No. 1, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">dminap@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6589-2164</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Секачева</surname><given-names>Марина Игоревна</given-names></name><name name-style="western" xml:lang="en"><surname>Sekacheva</surname><given-names>Marina I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор директор института персонализированной медицины федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>PhD, Professor, Director of the Institute of Personalized Medicine, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">sekacheva_m_i@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5938-8917</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соколова</surname><given-names>Анастасия Андреевна</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolova</surname><given-names>Anastasiya A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук профессор кафедры факультетской терапии № 1 федерального государственного автономного образовательного учреждения высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет), Москва, Российская Федерация</p></bio><bio xml:lang="en"><p>Professor of the Department of Faculty Therapy No. 1, Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation, Moscow, Russian Federation</p></bio><email xlink:type="simple">sokolovastasya2@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)<country>Россия</country></aff><aff xml:lang="en">Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Ministry of Health of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2025</year></pub-date><volume>14</volume><issue>1</issue><fpage>169</fpage><lpage>179</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Заикина М.П., Ткачёв М.И., Когай В.В., Табаченкова Е.С., Кудрявцева А.А., Напалков Д.А., Секачева М.И., Соколова А.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Заикина М.П., Ткачёв М.И., Когай В.В., Табаченкова Е.С., Кудрявцева А.А., Напалков Д.А., Секачева М.И., Соколова А.А.</copyright-holder><copyright-holder xml:lang="en">Zaikina M.P., Tkachev M.I., Kogaj V.V., Tabachenkova E.S., Kudryavceva A.A., Napalkov D.A., Sekacheva M.I., Sokolova A.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nii-kpssz.com/jour/article/view/1570">https://www.nii-kpssz.com/jour/article/view/1570</self-uri><abstract><sec><title>Основные положения</title><p>Основные положения </p><p>Впервые продемонстрировано, что такие факторы, как артериальная гипертензия, периферический атеросклероз и перенесенные сердечно-сосудистые события (инфаркт или инсульт), достоверно повышают риски как венозных, так и артериальных тромбоэмболических осложнений у пациентов с сочетанием сердечно-сосудистых заболеваний и злокачественных новообразований. Полученные результаты подчеркивают необходимость пересмотра существующих шкал оценки риска тромбозов у онкологических больных и разработки более точных профилактических подходов, включая использование антикоагулянтной терапии.</p></sec><sec><title> </title><p> </p></sec><sec><title>Аннотация</title><p>Аннотация</p></sec><sec><title>Актуальность</title><p>Актуальность. Сердечно-сосудистые заболевания (ССЗ) и злокачественные новообразования (ЗНО) являются ведущими причинами смертности в мире. Как правило, ССЗ и рак рассматриваются как две изолированные патологии, однако доказана потенциальная кардиотоксичность у пациентов, получающих химио- или лучевую терапию при лечении ЗНО. Несмотря на обилие данных в мировой литературе, до сих пор отсутствуют исследования, посвященные оценке связи тромбоэмболических осложнений (ТЭО), ЗНО и ССЗ.</p></sec><sec><title>Цель</title><p>Цель. Изучить влияние ССЗ и факторов риска на вероятность развития тромбоэмболических осложнений у пациентов с ЗНО.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен ретроспективный анализ пациентов с ЗНО, которые проходили лечение в Университетской клинической больницы № 1 Сеченовского Университета в период с 1 января 2021 г. по 31 декабря 2023 г. на базе. В исследование включены 877 пациентов с гистологически подтвержденными ЗНО, ассоциированными с высоким и очень высоким риском развития тромбозов (желудок, поджелудочная железа, легкие, яички, яичники, матка, молочная железа (фенотип HER 2+)). </p></sec><sec><title>Результаты</title><p>Результаты. Выявлено, что пациенты с более высокими стадиями распространенности первичной опухоли (Т), а также метастазами в регионарные лимфатические узлы (N) и отдаленными метастазами (M) имели высокий риск развития ТЭО. Также к факторам, повышающим риск ТЭО, можно отнести наличие артериальной гипертензии (p = 0,01), заболевания периферических артерий (p = 0,001), перенесенного инфаркта или инсульта (p = 0,001), сахарного диабета 2-го типа (p = 0,009).</p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с ТЭО чаще встречались артериальная гипертензия, периферический атеросклероз, перенесенное сердечно-сосудистое событие (инфаркт миокарда или острое нарушение мозгового кровообращения), хроническая сердечная недостаточность и сахарный диабет 2-го типа. По результатам регрессионного анализа значимыми оказались степень распространенности первичной опухоли и наличие периферического атеросклероза.</p></sec></abstract><trans-abstract xml:lang="en"><p>HighlightsIt has been demonstrated for the first time that factors such as arterial hypertension, peripheral atherosclerosis, and previous cardiovascular events (heart attack or stroke) significantly increase the risks of both venous and arterial thromboembolic complications in patients with a combination of cardiovascular diseases and malignant neoplasms. The results obtained emphasize the need to review existing scales for assessing the risk of thrombosis in cancer patients and to develop more accurate preventive approaches, including the use of anticoagulant therapy.</p><sec><title>Background</title><p>Background. Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide. Although CVD and cancer are generally considered isolated diseases, potential cardiotoxicity has been observed in patients receiving chemotherapy or radiation therapy for cancer treatment. Despite the extensive data in the literature, studies examining the relationship between thromboembolic complications, cancer, and CVD remain limited, necessitating further exploration of this issue.</p></sec><sec><title>Aim</title><p>Aim. To investigate the association between cardiovascular diseases and cancer concerning the risk of developing and progressing thromboembolic complications.</p></sec><sec><title>Methods</title><p>Methods. We retrospectively screened patients with cancer treated between January 1, 2021, and December 31, 2023, at University Clinical Hospital No. 1 of Sechenov University. The study included 877 patients (ages 19 to 93 years, median age 63 years) with histologically confirmed cancer with a high and very high risk of thrombosis (stomach, pancreas, lung, testicles, ovaries, uterus, breast (HER2+ phenotype)).</p></sec><sec><title>Results</title><p>Results. Our findings indicated that patients with higher stages of the primary tumor (T), regional lymph node metastases (N), and distant metastases (M) had a significantly elevated risk of thrombosis. Additionally, the presence of arterial hypertension (p = 0.01), peripheral atherosclerosis (p = 0.001), history of myocardial infarction and stroke (p = 0.001), and type 2 diabetes mellitus (p = 0.009) were identified as significant risk factors.</p></sec><sec><title>Conclusion</title><p>Conclusion. This study demonstrates for the first time that arterial hypertension, peripheral atherosclerosis, diabetes mellitus and a history of myocardial infarction and stroke increase the risks of both venous and arterial venous thromboembolism in patients with cancer and cardiovascular disease. According to the results of the regression analysis, the extent of the primary tumor (T) and the presence of peripheral atherosclerosis appeared to be significant factors.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Рак</kwd><kwd>Венозный тромбоз</kwd><kwd>Артериальный тромбоз</kwd><kwd>Онкологическое заболевание</kwd><kwd>Сердечно-сосудистое заболевание</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Cancer</kwd><kwd>Venous thrombosis</kwd><kwd>Arterial thrombosis</kwd><kwd>Cancer</kwd><kwd>Cardiovascular disease</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Авторы заявляют об отсутствии финансирования исследования.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">ReFaey K, Tripathi S, Grewal SS, et al. Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):645-653. doi:10.1016/j.mayocpiqo.2021.05.005</mixed-citation><mixed-citation xml:lang="en">ReFaey K, Tripathi S, Grewal SS, et al. Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. Mayo Clin Proc Innov Qual Outcomes. 2021;5(3):645-653. doi:10.1016/j.mayocpiqo.2021.05.005</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. Longo DL, ed. N Engl J Med. 2016;375(15):1457-1467. doi:10.1056/NEJMra1100265</mixed-citation><mixed-citation xml:lang="en">Moslehi JJ. Cardiovascular Toxic Effects of Targeted Cancer Therapies. Longo DL, ed. N Engl J Med. 2016;375(15):1457-1467. doi:10.1056/NEJMra1100265</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">de Wall C, Bauersachs J, Berliner D. Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38(4):361-371. doi:10.1007/s10585-021-10106-x</mixed-citation><mixed-citation xml:lang="en">de Wall C, Bauersachs J, Berliner D. Cardiooncology-dealing with modern drug treatment, long-term complications, and cancer survivorship. Clin Exp Metastasis. 2021;38(4):361-371. doi:10.1007/s10585-021-10106-x</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">De Boer RA, Meijers WC, Van Der Meer P, Van Veldhuisen DJ. Cancer and heart disease: associations and relations. European J of Heart Fail. 2019;21(12):1515-1525. doi:10.1002/ejhf.1539</mixed-citation><mixed-citation xml:lang="en">De Boer RA, Meijers WC, Van Der Meer P, Van Veldhuisen DJ. Cancer and heart disease: associations and relations. European J of Heart Fail. 2019;21(12):1515-1525. doi:10.1002/ejhf.1539</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Satpathy C, Kumar Mishra T, Singh S, Jha AK. Reverse cardio-oncology: A budding concept. Indian Heart J. 2023;75(6):398-402. doi:10.1016/j.ihj.2023.09.004</mixed-citation><mixed-citation xml:lang="en">Satpathy C, Kumar Mishra T, Singh S, Jha AK. Reverse cardio-oncology: A budding concept. Indian Heart J. 2023;75(6):398-402. doi:10.1016/j.ihj.2023.09.004</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007;5(3):632-634. doi:10.1111/j.1538-7836.2007.02374.x</mixed-citation><mixed-citation xml:lang="en">Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis. 2007;5(3):632-634. doi:10.1111/j.1538-7836.2007.02374.x</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Streiff MB, Holmstrom B, Angelini D, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181-1201. doi:10.6004/jnccn.2021.0047</mixed-citation><mixed-citation xml:lang="en">Streiff MB, Holmstrom B, Angelini D, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181-1201. doi:10.6004/jnccn.2021.0047</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(11):1336-1349. doi:10.1016/j.jacc.2019.01.017</mixed-citation><mixed-citation xml:lang="en">Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(11):1336-1349. doi:10.1016/j.jacc.2019.01.017</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pateras I, Giaginis C, Tsigris C, Patsouris E, Theocharis S. NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Expert Opinion on Therapeutic Targets. 2014;18(9):1089-1101. doi:10.1517/14728222.2014.938051</mixed-citation><mixed-citation xml:lang="en">Pateras I, Giaginis C, Tsigris C, Patsouris E, Theocharis S. NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links. Expert Opinion on Therapeutic Targets. 2014;18(9):1089-1101. doi:10.1517/14728222.2014.938051</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Buziashvili JI, Stilidi IS, Mackeplishvili ST, et al. Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects. Annals RAMS. 2023;78(2):132-140. doi:10.15690/vramn8359</mixed-citation><mixed-citation xml:lang="en">Buziashvili JI, Stilidi IS, Mackeplishvili ST, et al. Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects. Annals RAMS. 2023;78(2):132-140. doi:10.15690/vramn8359</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. doi:10.1186/s12199-018-0740-1</mixed-citation><mixed-citation xml:lang="en">Murata M. Inflammation and cancer. Environ Health Prev Med. 2018;23(1):50. doi:10.1186/s12199-018-0740-1</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343-351. doi:10.1016/j.atherosclerosis.2017.06.001</mixed-citation><mixed-citation xml:lang="en">Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: Evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343-351. doi:10.1016/j.atherosclerosis.2017.06.001</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Genovesi S, Giussani M, Orlando A, Lieti G, Viazzi F, Parati G. Relationship between endothelin and nitric oxide pathways in the onset and maintenance of hypertension in children and adolescents. Pediatr Nephrol. 2022;37(3):537-545. doi:10.1007/s00467-021-05144-2</mixed-citation><mixed-citation xml:lang="en">Genovesi S, Giussani M, Orlando A, Lieti G, Viazzi F, Parati G. Relationship between endothelin and nitric oxide pathways in the onset and maintenance of hypertension in children and adolescents. Pediatr Nephrol. 2022;37(3):537-545. doi:10.1007/s00467-021-05144-2</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222-1231. doi:10.1634/theoncologist.2016-0414</mixed-citation><mixed-citation xml:lang="en">Gerotziafas GT, Taher A, Abdel-Razeq H, et al. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222-1231. doi:10.1634/theoncologist.2016-0414</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346. doi:10.1002/cncr.23062</mixed-citation><mixed-citation xml:lang="en">Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339-2346. doi:10.1002/cncr.23062</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. doi:10.1038/s41572-022-00336-y</mixed-citation><mixed-citation xml:lang="en">Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. doi:10.1038/s41572-022-00336-y</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: A population-based cohort study. Thromb Haemost. 2017;117(01):57-65. doi:10.1160/TH15-08-0686</mixed-citation><mixed-citation xml:lang="en">Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: A population-based cohort study. Thromb Haemost. 2017;117(01):57-65. doi:10.1160/TH15-08-0686</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagulation &amp; Fibrinolysis. 2008;19(2):159-165. doi:10.1097/MBC.0b013e3282f54558</mixed-citation><mixed-citation xml:lang="en">Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagulation &amp; Fibrinolysis. 2008;19(2):159-165. doi:10.1097/MBC.0b013e3282f54558</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: What Have We Learned and What Questions Remain? Drugs &amp; Aging. 1999;15(6):419-422. doi:10.2165/00002512-199915060-00001</mixed-citation><mixed-citation xml:lang="en">Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: What Have We Learned and What Questions Remain? Drugs &amp; Aging. 1999;15(6):419-422. doi:10.2165/00002512-199915060-00001</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jezovnik MK, Poredos P, Lusa L. Idiopathic Venous Thrombosis is Associated with Preclinical Atherosclerosis. JAT. 2010;17(3):304-311. doi:10.5551/jat.3079</mixed-citation><mixed-citation xml:lang="en">Jezovnik MK, Poredos P, Lusa L. Idiopathic Venous Thrombosis is Associated with Preclinical Atherosclerosis. JAT. 2010;17(3):304-311. doi:10.5551/jat.3079</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bai J, Ding X, Du X, Zhao X, Wang Z, Ma Z. Diabetes is associated with increased risk of venous thromboembolism: A systematic review and meta-analysis. Thrombosis Research. 2015;135(1):90-95. doi:10.1016/j.thromres.2014.11.003</mixed-citation><mixed-citation xml:lang="en">Bai J, Ding X, Du X, Zhao X, Wang Z, Ma Z. Diabetes is associated with increased risk of venous thromboembolism: A systematic review and meta-analysis. Thrombosis Research. 2015;135(1):90-95. doi:10.1016/j.thromres.2014.11.003</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Zhan Y, Fu X, Bi W, Li G. Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2024;46(2):2431149. doi:10.1080/0886022X.2024.2431149</mixed-citation><mixed-citation xml:lang="en">Zhan Y, Fu X, Bi W, Li G. Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2024;46(2):2431149. doi:10.1080/0886022X.2024.2431149</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lees JS, Ho F, Parra-Soto S, et al. Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study. eClinicalMedicine. 2021;38:101030. doi:10.1016/j.eclinm.2021.101030</mixed-citation><mixed-citation xml:lang="en">Lees JS, Ho F, Parra-Soto S, et al. Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study. eClinicalMedicine. 2021;38:101030. doi:10.1016/j.eclinm.2021.101030</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Roach REJ, Lijfering WM, Tait RC, et al. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. Journal of Thrombosis and Haemostasis. 2015;13(10):1815-1822. doi:10.1111/jth.13116</mixed-citation><mixed-citation xml:lang="en">Roach REJ, Lijfering WM, Tait RC, et al. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. Journal of Thrombosis and Haemostasis. 2015;13(10):1815-1822. doi:10.1111/jth.13116</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Pastori D, Cormaci VM, Marucci S, et al. A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. Int J Mol Sci. 2023;24(4):3169. doi:10.3390/ijms24043169</mixed-citation><mixed-citation xml:lang="en">Pastori D, Cormaci VM, Marucci S, et al. A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. Int J Mol Sci. 2023;24(4):3169. doi:10.3390/ijms24043169</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
